Acarix, a Copenhagen, Denmark-based developer of acoustic monitoring of coronary artery diseases of the heart, raised € 3.6m in funding.
SEED Capital re-invested in Acarix.
The company intends to use the funding for market saturation and promotion of their technology, which has shown promising clinical results based on tests of more than 800 heart patients and volunteers.
Led by CEO Peter Samuelsen and COO Claus BV Christensen, Acarix has developed the CADScor® System for early diagnosis of Coronary Artery Disease (CAD), which is based on recording of acoustic murmurs in the heart, caused by narrowed coronary arteries. The size of the device is equivalent to a cell phone and it is attached to the chest of the patient via a specially developed patch.
The company, which is based on pioneering research performed at the Aalborg University, Denmark, initiated in 2004, is currnetly located at the research park Scion-DTU.
It was established in 2009 as a spin-out company from Coloplast A/S with Coloplast A/S and Aalborg University as the major shareholders.